Pharmaceutical maker Amgen will lower the sticker price of its cholesterol drug Repatha (generic: evolocumab) by 60% to $5,850 a year, it announced Wednesday. Repatha is a PCSK9 inhibitor shown to ...

Repatha, a new drug from Amgen, prevents heart attacks and strokes better than any medicine since the cholesterol-lowering statin drugs that are a daily preventative for millions of middle-aged people ...

The approval of evolocumab (Repatha) creates competition in the new class of PCSK9 cholesterol-fighting therapies and managed care plans and pharmacy benefit managers are expected to take full ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...